Baker McKenzie advised Minoryx Therapeutics on the deal. Clifford Chance advised the Neuraxpharm Group. Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments...
Minoryx Therapeutics and Neuraxpharm Group’s Development of a New CNS Therapy in Europe
AXA IM, OMERS and Goldman Sachs’ Majority Stake Acquisition in Amedes
Orrick Herrington & Sutcliffe advised AXA Investment Managers on the deal. Clifford Chance LLP advised the consortium and Sullivan & Cromwell LLP advised GS Infrastructure. Latham...